Anticoagulant management in interventional cardiology: Monitoring heparin using ACT instrumentation

Cardiovascular Reviews and Reports

Volumn 19, Issue 11, 1998, Pages 34-47

  David Ogilby, J ^a   Carville, David G M ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SOUTH BEND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; CARDIOLOGY; CARDIOPULMONARY BYPASS; HEART CATHETERIZATION; HEPARINIZATION; HUMAN; INTERVENTIONAL RADIOLOGY; MEDICAL INSTRUMENTATION; REVIEW;

EID: 0031787062     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Nieuwenhuizen W, Hoegee-De Nobel E, Laterveer R. A rapid monoclonal antibody-based enzyme immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma. Thromb Haemost. 1992;68:273-277.
2. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorders. Philadelphia: W.B. Saunders; 1992:1-16.
3. Samama MM, Conard J, Horellou MH, et al. Coagulation abnormalities predisposing to the development of deep vein thrombosis. In: Bergqvist D, Comerota AJ, Nicolaides AN, Scurr JH (eds). Prevention of Venous Thromboembolism. Sunland, CA: Med-Orion; 1994:43-56.
4. Mosseson MW. Fibrin polymerization and its regulatory role in hemostasis.y Lab Clin Med. 1990;! 16:8-17.
5. Bick RL. Disseminated intravascular coagulation: A clinical/laboratory study of 48 patients. Ann N YAcad Sei. 1981;370:843.
6. Vogel G, Spanuth E. Predictive value of fibrin monomers in postoperative deep vein thrombosis. Klin Wochenscher. 1990:68:1020-1026.
7. Ogilby JD, Kopelman HA, Klein LW, et al. Adequate heparinization during PTCA: Assessment using activated clotting times. Calk Cardio Diag. 1989;I8:206-209.
8. Sughayer M, Arkin CF. Monitoring coagulation during and after cardiopulmonary bypass surgery. Thromb Haemost. 1990;12:l-7.
9. Califf RA, Willerson JT. Percutaneous transluminal coronary' angioplasty: Prevention of occlusion and restenosis. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorders. Philadelphia: W.B. Saunders; 1992:389-408.
10. Ferguson JJ. Conventional antithrombotic approaches. Am Heart J. 1995; 130:651-657.
11. Levine MN, Hirsch J. Hemorrhagic complications of longterm antithrombotic creatment. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorders. Philadelphia: W.B. Saunders; 1992:515-522.
12. Morgan CH, Penner JA. Bleeding complications during surgery: Part 1. Defects of primary hemostasis and congenital coagulation. Lab Med. 1986; 17:207-212.
13. Poller L, Hirsli J. Optimal therapeutic ranges for oral anticoagulation. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorders. Philadelphia: W.B. Saunders; 1992:161-173.
14. Klein LW, Aganval JB. When we "act" on ACT levels: Activated clotting time measurements to guide heparin administration during and after interventional procedures. Cathet Cardiovasc Diagn. 1996;37:154-157.
15. Carell R, Skinner R, Jin L, et al. Structural mobility of antithrombin and its aodulation by heparin. Throm Haemest. I997;78:516-519.
16. Verstraete M, Wessier S. Heparins and oral anticoagulants. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorders. Philadelphia: W.B. Saunders; 1992:121-140.
17. Hirsch J. Optimal therapeutic ranges for unfractionated heparin and low molecular weight heparin. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorders. Philadelphia: W.B. Saunders; 1992:147-160.
18. Choay J, Petitou M, Lormeau JC, et al. Structure activity relationship in heparin: A synthetic pentassacharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun. 1983;! 16:492-499.
19. Rosenberg RD. The heparin-antithrombin system: A natural anticoagulant mechanism. In: Colman RW, Hirsch J, Marder VJ, et al (eds). Haemostasis and Thrombosis: Basic Principles and Clinical Practice. 2nd Ed. Philadelphia: J.B. Lippincott; 1987:1373-1392.
20. Thompson AR, Harker LA. Mechanisms of action of antithrombotic agents. In: Manual of Hemostasis and Thrombosis 3rd Ed. Philadelphia: F.A. Davis Co; 1988:147-162.
21. Hattersley PC. Heparin Anticoagulation. In: Koepke SA (ed). Laboratory Haematology. New York: Churchill Livingstone; 1984.
22. Sutton JM, Anderson K. For the EPIC study group. Body weight and heparin dosing influence bleeding complications with c7E3 antiplatelet antibody. Circulation. 1993;88(suppl 1:209.
23. Freeman MR, Langer A, Wilson RF, et al. Thrombolysis in unstable angina: Randomized double blind trial of tPA and placebo. Circulation. 1992;85:I50-163.
24. Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig: The in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476-1485.
25. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high risk coronary angioplasty. N EngJ Med. 1994:330:956-961.
26. Ogilby JD, Untereker WJ. Antithrombotic management of patients with unstable angina in the catheterization laboratory. Cardia /n;mwtioN;1993;3:19-22.
27. Ogilby JD, Untereker WJ, Corin WJ, et al. Variability of effective anticoagulation for PTCA is dependent upon heparin potency. Circulation. 1991;84(suppl l):II-592.
28. Barrowcliffe TW, Johnson EA, Eggleton CA, et al. Anticoagulant activities of high and low molecular weight fractions. BrJ Haemalol. 1979;41:573.
29. Pesola GR, Pesola DA. Heparin (losing for percutaneous coronary angioplasty; use of bosy surface area to improve initial activated clotting time values. Clin Cardiol. 1997;20:1006-1009.
30. Habbub MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin./lrcA Intern Med. 1987;147:857-8GO.
31. Callus AS. Replacement therapy in antithrombin III deficiency. Transfus Med Rev. 1989;3:253-263.
32. Bull BS, Korman RA, Huse WM, et al. Heparin therapy during extracorporeal circulation I. Problems inherent in existing protocols.y Thorac Cardiovasc Surg. 1975;G9:674-684.
33. Ponari O, Corsi M, Manotti C, et al. Predictive value of preoperative in vitro and in vivo studies for correct individual heparinization in cardiac surgery./ Thorac Cardiovasc Surg. 1979;78:87-94.
34. Blumenthal RS, WolffMR, Resar JR, et al. Preprocedural anticoagulation does not reduce angioplasty heparin requirements. Am HeartJ. 1993; 125:1221-1225.
35. Wessier S, Morris LE. Studies in intravascular coagulation IV. The effect of heparin and dicoumarol on serum induced venous thrombosis. Circulation. 1956; 12:563-566.
36. Struvler GP, Bittner DL. The partial thrombolastin time (cephalin time) in anticoagulant therapy. AmJ Clin Pat/iol. 1962;38:473-48I.
37. Kerensky RA, Azar GJ, Bertolet B, et al. Venous activated clotting time after intra-arterial heparin: Effect of site administration and timing of sampling. Cathet Cardiovasc Diagn. 1996;37:151-153.
38. Reich DL. Monitoring hemostasis in the perioperative period: Anticoagulation control./ Cardiolhorac VascAnesth. I991;5:4-7.
39. Carter AJ, Hicks K, Heldman AW, et al. Clinical evaluation of a microsaniple coagulation analyzer, and comparison with existing techniques. Cathet Cardiovasc Diagn. 1996;39:97-102.
40. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty .J Am Coll Cardiol. 1994;23:1061-I065.
41. Fristoe L. Clinical evaluation of five point of care coagulation monitors in cardiac surgery. Am Sect. In press.
42. Avendando A, Ferguson JJ. Comparison of Hemochron and Hemotec activated coagulation time target values during percutaneous transliuminal coronary angioplasty.//1m Coll Cardiol. 1994;23:907-910.
43. Narins CR, Hillegass WB, Nelson CL, et al., Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 1996;93:667-671.
44. Sherman DG, Hart RG. Stroke and transient ischemie attack: Thromboembolsim and antithrombotic therapy. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorders. Philadelphia: W.U. Saunders; 1992:409-122.
45. Lincoff AM, TchengJE, CaliffRM, et al. Standard verus lowdose weight adjusted heparin in patients treated with the platelet glycoprotein Ilb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularhalion.AmJ Cardiol. 1997;79:286-291.
46. Verstraete M. Novelties in antithrombotic and thrombolytic therapy: A latest update. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorders. Philadelphia: W.B. Saunders; 1992:529-544.